TXG 10x Genomics, Inc.
10x Genomics, Inc. (TXG) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 82% planned / 18% discretionary
Largest single sale: $2.0M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Saxonov Serge 5 fills | Chief Executive Officer | Sell 10b5-1 | 25,000 | $81.22 | $2.0M | 1,074,249 −2.3% of holding | |
| SULIMAN SHEHNAAZ 5 fills | Director | Sell 10b5-1 | 5,723 | $81.19 | $464.7K | 29,223 −16.4% of holding | |
| Taich Adam 3 fills | Chief Financial Officer | Sell 10b5-1 | 46,388 | $64.57 | $3.0M | 361,526 −11.4% of holding | |
| STUELPNAGEL JOHN R 3 fills | Director | Sell | 20,000 | $61.75 | $1.2M | 341,424 −5.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.